SEP 1 9 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

C. Liaw et al.

: Art Unit: 1646

Serial No.:

09/875,076

: Examiner: P. Mertz

Filed:

June 6, 2001

.

For:

NUCLEIC ACID ENCODING

HUMAN G PROTEIN-COUPLED

RECEPTORS

Via Express Mail Label No: EV147553662US Date Sent: September 19, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the Form PTO/SB/08B submitted herewith. A copy of each listed reference is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

More than three months have elapsed since the filing of the abovereferenced application and a first (non-Final) Official Action has been received. No Final

09/25/2003 ANABII 000/20032 501275 096/2076

Action or Notice of Allowance has yet been received and it is presumed that none has yet been mailed. Accordingly, please charge the required fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1275.

Respectfully submitted,

Michael A Patané

Registration No. 42,982 Attorney for Applicants

Enclosures:

Form PTO/SB/08B Copy of References Cited

Dated:

Cozen O'Connor 1900 Market Street – 5th Floor Philadelphia, PA 19103

Tel: 215-665-2000 Fax: 215-665-2013

AREN-11.US9.DIV (0239)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1963, no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Ad Substitute for form 1449A/PTO Complete if Known 09/875.076 Application Number INFORMATION DISCLOS June 6, 2001 Filing Date STATEMENT BY APPLICA First Named Inventor C. Liaw et al. Art Unit 1646 (use as many sheets as necessary) Examiner Name Prema Maria Mertz

Attorney Docket Number

Sheet

of 2

	Cite No '	Document Number		Name of Patentee or Applicant of	B. C. L. C. L. William B. L.
Examiner Initials *		Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines. Where Releva Passages or Relevant Figures Appear
		US-6,555,344 B1	04/29/2003	Matsumoto et al.	
		US-			
		US-			
	!	US-			
		US-			
		US-			
	ĺ	US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	-					
	-					
						-
	-					
			-			

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov.or.MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(05-03)

Approved for use through 04/30/2003 OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

rsons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995

Substitute for form 1449A/PTO Complete if Known 09/875,076 **Application Number** INFORMATION DISCLOSURE June 6, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor C. Liaw et al. Group Art Unit 1646 (use as many sheets as necessary) **Examiner Name** Prema Maria Mertz AREN-11.US9.DIV (0239) of Attorney Docket Number Sheet

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-in number(s), publisher, city and/or country where published.			
		Hirsch et al., "Neuronal Vulnerability in Parkinson's Disease", J Neural Transm Suppl. 1997,50:79-88		
		Hulley et al, "Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons In Vivo", European Journal of Neuroscience, Vol. 7, pp. 2431-2440, 1995		
		Berridge, Michael J., "Inositol trisphosphate and calcium signalling", Nature, Vol. 361, 28 January 1993		
		Wilson et al., "Orphan G-Protein-coupled receptors: the next generation of drug targets?", British Journal of Pharmacology (1998) 125, 1387-1392		
		Hegyi et al., "The Relationship between Protein Structure and Function: a Comprehensive Survey with Application to the Yeast Genome", J. Mol. Biol. (1999) 288, 147-164		
		Kasuya et al., "Three-dimensional Structure Analysis of PROSITE Patterns", J. Mol. Biol. (1999) 286, 1673-1691		

$\overline{}$	 _	
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.